Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin for Ischemic Reperfusion Injury in CABG
NCT02984111Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2016
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of erythropoietin in myocardial reperfusion injury (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Change in Interleukin 6, Change in YKL-40 and 1 more. Started Jan 2016; status: completed.
02
Drugs
erythropoietin
03
Conditions
myocardial reperfusion injury
Beyond the preview
Go deeper on NCT02984111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02984111.